Taysha gene therapies presents preclinical data on tsha-102 for rett syndrome demonstrating cellular regulation of mecp2 expression in key mouse models at the american society of gene and cell therapy 26th annual meeting

New preclinical data after neonatal administration in wild-type mice showed no detectable impact on survival, neurobehavioral functions and overall health, suggesting tsha-102, engineered with novel mirare technology, avoided toxic overexpression of mecp2 within cells already expressing mecp2
TSHA Ratings Summary
TSHA Quant Ranking